Sangamo Therapeutics (SGMOQ) Non-Current Deffered Revenue (2012 - 2025)

Sangamo Therapeutics' Non-Current Deffered Revenue history runs 14 years deep, the most recent figure standing at $5.9 million for Q4 2025.

• On a quarterly basis, Non-Current Deffered Revenue changed 0.0% year-over-year to $5.9 million in Q4 2025; TTM through Dec 2025 was $5.9 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $5.9 million, changed 0.0% from the prior year.
• Non-Current Deffered Revenue was little changed at $5.9 million in Q4 2025 per SGMOQ's latest filing, from $5.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $222.3 million in Q1 2021 and bottomed at $1.8 million in Q1 2023.
• The 5-year median for Non-Current Deffered Revenue is $112.5 million (2022), against an average of $93.6 million.
• Across the five-year window, Non-Current Deffered Revenue jumped 195.29% in 2021 and sank 98.79% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $166.8 million in 2021, then sank by 34.42% to $109.4 million in 2022, then sank by 98.34% to $1.8 million in 2023, then surged by 223.46% to $5.9 million in 2024, then changed by 0.0% to $5.9 million in 2025.
• Per Business Quant, the three latest SGMOQ Non-Current Deffered Revenue figures stand at $5.9 million (Q4 2025), $5.9 million (Q3 2025), and $5.9 million (Q2 2025).